← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 3
Cevostamab (Cevostamab)
Genentech, Inc.·Multiple Myeloma
10 trials
Overview
Program
Cevostamab
Overview
Company
Genentech, Inc.
Overview
Modality
ANTIBODY
Overview
Target
Multiple Myeloma
Overview
Indication
Relapsed or Refractory Multiple Myeloma
Overview
Phase
PHASE_3
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies.. Bispecific antibodies have emerged as a transformative immunotherapeutic strategy in multiple myeloma (MM). Early constructs such as BiTEs paved the way for full-length IgG-based antibodies with improved pharmacokinetics and safety profiles. As of 2025, teclistamab, elranatamab, linvoseltamab (…
Toxicology
CRS
Reported
Clinical
Safety signal
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies.. Bispecific antibodies have emerged as a transformative immunotherapeutic strategy in multiple myeloma (MM). Early constructs such as BiTEs paved the way for full-length IgG-based antibodies with improved pharmacokinetics and safety profiles. As of 2025, teclistamab, elranatamab, linvoseltamab (…
Clinical
Program phase
PHASE_3